Here are four things to know:
1. The panel voted that Merck Pharmaceuticals, the company that develops sugammadex, has provided sufficient information to characterize the risk for hypersensitivity/anaphylaxis as well as the risk for cardiac dysrhythmias.
2. Sugammadex binds to rocuronium and vecuronium, which induce paralysis during surgery.
3. The FDA has not approved the drug several times due to concerns that include adverse events.
4. The committee’s recommendation is not binding and the FDA is scheduled to make a decision by Dec. 19.
More articles on anesthesia:
ASA names Dr. James Grant first VP: 5 points
Sheridan acquires Valley Anesthesiology & Pain Consultants: 3 things to know
ASA names Dr. Mark Neuman 2015 Presidential Scholar Award: 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
